Acute kidney injury following cardiac surgery remains one of the most feared postoperative complications, affecting up to 30% of patients and dramatically worsening long-term outcomes. Whether SGLT2 inhibitors — already proven kidney-protective in chronic disease settings — could extend that protection into the high-stress perioperative window has been an open and clinically urgent question until now.
This randomized trial published in JAMA investigated dapagliflozin, an SGLT2 inhibitor, specifically in the context of cardiac surgery — a population uniquely vulnerable to acute kidney injury due to cardiopulmonary bypass, hemodynamic instability, and contrast exposure. The trial evaluated perioperative AKI incidence as the primary endpoint, building on prior meta-analytic evidence showing SGLT2 inhibitors reduce serious AKI by 20–26% across chronic disease populations. The cardiac surgery cohort represents a distinct and more acute mechanistic challenge than the outpatient chronic kidney disease or heart failure settings where these drugs established their reputation.
This finding carries real translational weight. SGLT2 inhibitors are thought to confer kidney protection partly through reducing glomerular hyperfiltration, modulating tubular metabolism toward more efficient oxygen utilization, and attenuating inflammation — mechanisms plausibly relevant to ischemia-reperfusion injury during surgery. However, the perioperative context also introduces safety considerations: SGLT2 inhibitors have been associated with euglycemic diabetic ketoacidosis when continued through surgical fasting periods, a risk that has led many institutions to discontinue them preoperatively. This trial's design and timing around drug administration will be critical details for readers to assess in the full text. As a prospective randomized trial published in JAMA — rather than a secondary analysis or observational cohort — it carries substantially more causal weight than the meta-analyses that preceded it. If the protective signal holds with an acceptable safety profile, this could reshape perioperative cardiac protocols for a broad patient population.